MedTrace Logo

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

NCT03587844 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2026-04-03

No results posted yet for this study

Summary

The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.

Conditions

  • Mycosis Fungoides
  • Lymphomatoid Papulosis
  • Sezary Syndrome

Interventions

DRUG

brentuximab vedotin

MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.

DRUG

brentuximab vedotin

LyP Brentuximab vedotin 0.9 mg/kg2

DRUG

brentuximab vedotin

MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1

Sponsors & Collaborators

Principal Investigators

  • Alison Moskowitz, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-03
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03587844 on ClinicalTrials.gov